Tag: tafamidis
-
Stabilizers in ATTR-CM — tafamidis and acoramidis built the first hard-outcome standard of care, but the “next-generation” increment is not proven mortality superiority
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All efficacy figures are attributed to the sponsoring trial or company (ATTR-ACT to Pfizer/NEJM 2018; ATTRibute-CM to BridgeBio/NEJM 2024). Cross-trial comparisons are not head-to-head. The “near-complete (≥90%) stabilization” claim is…
Uthando Nethemba 